- Report
- January 2020
- 142 Pages
Global
From €5973EUR$6,250USD£5,082GBP
- Report
- August 2022
- 115 Pages
Global
From €4300EUR$4,500USD£3,659GBP
- Report
- September 2018
Global
From €4300EUR$4,500USD£3,659GBP
- Report
- November 2023
- 18 Pages
Colombia
- Report
- November 2023
- 20 Pages
Israel
- Report
- October 2023
- 18 Pages
Thailand
- Report
- September 2023
- 29 Pages
Canada
- Report
- September 2023
- 12 Pages
Slovakia
- Report
- August 2023
- 14 Pages
Sweden
- Report
- July 2023
- 14 Pages
Germany
- Report
- July 2023
- 14 Pages
Chile
- Report
- July 2023
- 19 Pages
Poland
- Report
- June 2023
- 16 Pages
Turkey
- Report
- June 2023
- 14 Pages
South Africa
- Report
- May 2023
- 16 Pages
Lithuania
- Report
- July 2022
- 14 Pages
Luxembourg
- Report
- June 2022
- 11 Pages
Japan
- Report
- June 2022
- 17 Pages
Mexico
- Report
- June 2022
- 13 Pages
United States
- Report
- May 2022
- 20 Pages
Paraguay
The Cannabinoids market, within the context of analgesics, refers to the range of products derived from the cannabis plant that are used for their pain-relieving properties. These substances interact with the body's endocannabinoid system to help alleviate both acute and chronic pain. The market encompasses a variety of cannabinoids, with tetrahydrocannabinol (THC) and cannabidiol (CBD) being the most well-known and extensively studied. These compounds are available in several forms, including oils, tinctures, edibles, patches, and pills, and are recommended for a range of conditions, such as neuropathic pain, inflammation, and muscle soreness. With the evolving legal landscape and growing acceptance of medical cannabis in many regions, the role of cannabinoids as analgesics continues to develop, and their use is being increasingly integrated into pain management protocols.
Some companies that have a notable presence in the cannabinoid analgesics market include GW Pharmaceuticals, which is well-known for its cannabinoid-based prescription medicines; Canopy Growth Corporation, a diversified cannabis and cannabinoid-based consumer product company; Tilray, which engages in the research, cultivation, production, and distribution of medical cannabis and cannabinoids; and Aurora Cannabis, which specializes in the production and distribution of medical cannabis. Each of these companies focuses on leveraging the therapeutic potential of cannabinoids and developing a range of products aimed at improving patient outcomes in pain management. Show Less Read more